These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
184 related items for PubMed ID: 19339002
1. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Ozcelik B, Turkyilmaz C, Ozgun MT, Serin IS, Batukan C, Ozdamar S, Ozturk A. Fertil Steril; 2010 Mar 15; 93(5):1609-14. PubMed ID: 19339002 [Abstract] [Full Text] [Related]
2. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats]. Peng P, Yang DZ, Zheng CY, Mo YQ, He YM, Zhang QX. Zhonghua Fu Chan Ke Za Zhi; 2007 Aug 15; 42(8):546-50. PubMed ID: 17983495 [Abstract] [Full Text] [Related]
6. Long-term effects of GnRH agonist, GnRH antagonist, and estrogen plus progesterone treatment on apoptosis related genes in rat ovary. Saatli B, Kizildag S, Posaci C, Dogan E, Koyuncuoglu M, Ulukus EC, Atabey N. Fertil Steril; 2009 May 15; 91(5 Suppl):2006-11. PubMed ID: 18829022 [Abstract] [Full Text] [Related]
8. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. Bildik G, Akin N, Senbabaoglu F, Sahin GN, Karahuseyinoglu S, Ince U, Taskiran C, Selek U, Yakin K, Guzel Y, Ayhan C, Alper E, Cetiner M, Balaban B, Mandel NM, Esen T, Iwase A, Urman B, Oktem O. Hum Reprod; 2015 Dec 15; 30(12):2912-25. PubMed ID: 26466909 [Abstract] [Full Text] [Related]
10. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: a mouse model. Tan SJ, Yeh YC, Shang WJ, Wu GJ, Liu JY, Chen CH. Eur J Obstet Gynecol Reprod Biol; 2010 Apr 15; 149(2):182-5. PubMed ID: 20074846 [Abstract] [Full Text] [Related]
11. Gonadotropin-releasing hormone agonist affects rat ovarian follicle development by interfering with FSH and growth factors on the prevention of apoptosis. Parborell F, Dain L, Tesone M. Mol Reprod Dev; 2001 Oct 15; 60(2):241-7. PubMed ID: 11553925 [Abstract] [Full Text] [Related]
14. Retrieval of immature oocytes after chemotherapy for Hodgkin's disease and prolonged ovarian down-regulation with gonadotropin-releasing hormone agonist. Azem F, Hasson J, Cohen T, Shwartz T, Mey-Raz N, Almog B, Amit A, Ben-Yosef D. Fertil Steril; 2009 Aug 15; 92(2):828.e1-2. PubMed ID: 19524895 [Abstract] [Full Text] [Related]
17. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome. Moon HS, Joo BS, Moon SE, Lee SK, Kim KS, Koo JS. Fertil Steril; 2008 Dec 15; 90(6):2172-8. PubMed ID: 18439601 [Abstract] [Full Text] [Related]
18. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. Kahraman K, Berker B, Atabekoglu CS, Sonmezer M, Cetinkaya E, Aytac R, Satiroglu H. Fertil Steril; 2009 Jun 15; 91(6):2437-44. PubMed ID: 18555238 [Abstract] [Full Text] [Related]
19. Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Dogan E, Saygili U, Posaci C, Tuna B, Caliskan S, Altunyurt S, Saatli B. Fertil Steril; 2004 Oct 15; 82 Suppl 3():1115-20. PubMed ID: 15474083 [Abstract] [Full Text] [Related]